Britain and America have finalized a landmark trade agreement that will keep no tariffs on UK drug exports going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the public health system. This commitment ensures that tariffs on these crucial exports will remain at zero for a timeframe of 36 months.
This deal comes after previous threats to significantly raise import taxes on branded drug imports, with figures discussed up to 100%.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," an announcement declared.
Commercial Impact
Pharmaceuticals represent one of the Britain's biggest exports to the US, which is by far the largest market for large companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of last September, the UK sold drugs totaling billions to the US. This figure made up 17.4% of total UK exports in that span.
"This deal protects work, boosts capital expenditure and facilitates the UK to establish itself as a global hub for medical research," a minister stated.
Specific British Pledges
The pact includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, repayments topped 20%.
Industry Background
This agreement comes amid a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were intensified by arguments that American consumers were charged several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial expansions have been pledged toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had decreased as a share of its resources over the past decade.
